托法替布单药或联合背景传统合成改善病情抗风湿药治疗三期类风湿关节炎人群安全性的汇总分析
该研究对六项三期双盲随机对照试验进行事后汇总分析,纳入3881例类风湿关节炎患者,比较托法替布5 mg与10 mg每日两次单药或联合传统合成改善病情抗风湿药的安全性。单药组严重不良事件、因不良事件停药、严重感染和带状疱疹的发生率数值上低于联合组,且带状疱疹与严重感染的95%置信区间不重叠。作者认为托法替布单药可能安全性事件较少,对传统合成改善病情抗风湿药不耐受的活动性类风湿关节炎患者具有有利的风险-获益特征。
要点
- 单药组严重不良事件发生率6.21-6.72 vs 联合组10.17-13.46,数值上更低。
- 单药组严重感染发生率1.57-1.66 vs 联合组3.39-3.56,95%置信区间不重叠。
- 单药组带状疱疹发生率1.95-2.93 vs 联合组4.37-4.99,95%置信区间不重叠。
核心结论
- 单药与联合治疗的安全性特征总体相似,但带状疱疹和严重感染等选定安全性事件在托法替布全单药组的发生率更低且95%置信区间不重叠。
- 作者认为托法替布单药可能较联合治疗安全性事件更少,对传统合成改善病情抗风湿药不耐受的活动性类风湿关节炎患者具有有利的风险-获益特征。
研究设计与样本
- 对六项托法替布5 mg和10 mg每日两次治疗类风湿关节炎的三期双盲随机对照试验进行事后汇总分析。
- 安全性分析共纳入3881例患者,其中单药研究1380例,联合传统合成改善病情抗风湿药研究2501例。
- 按单药或联合传统合成改善病情抗风湿药给药及基线糖皮质激素使用分层分析安全性。
主要发现
- 单药组严重不良事件发生率6.21-6.72 vs 联合组10.17-13.46。
- 单药组因不良事件停药发生率5.53-6.18 vs 联合组10.80-11.01。
- 单药组严重感染发生率1.57-1.66 vs 联合组3.39-3.56。
- 单药组带状疱疹发生率1.95-2.93 vs 联合组4.37-4.99。
- 上述选定不良事件发生率在单药组数值上低于联合组,与托法替布剂量或糖皮质激素使用无关。
关键数值与推荐
- 安全性评估包括严重不良事件、因不良事件停药、严重感染事件和带状疱疹的发生率,贯穿三期研究全程。
- 安慰剂组患者和事件数太少,无法充分评估联合治疗与单药治疗之间的效应。
临床怎么用
- 作者认为托法替布单药可能较联合治疗安全性事件更少,对传统合成改善病情抗风湿药不耐受的活动性类风湿关节炎患者具有有利的风险-获益特征。
局限性
- 安慰剂组患者和事件数太少,无法充分评估联合治疗与单药治疗之间的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This post-hoc, pooled analysis of Phase 3 studies of tofacitinib examined the safety of tofacitinib 5 and 10 mg twice daily (BID) when used as monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis (RA). METHODS: Pooled data from six double-blind, randomized controlled Phase 3 studies of tofacitinib 5 and 10 mg BID in patients with RA were analyzed for safety and stratified by administration as monotherapy (ORAL Solo: NCT00814307 and ORAL Start: NCT01039688) or in combination with csDMARDs (ORAL Sync: NCT00856544, ORAL Standard: NCT00853385, ORAL Scan: NCT00847613, and ORAL Step: NCT00960440), and by glucocorticoid use at baseline. Safety assessments included incidence rates (IRs) for serious adverse events (SAEs), discontinuations due to AEs, serious infection events, and herpes zoster (HZ), and were evaluated throughout the duration of the Phase 3 studies. RESULTS: In total, 3881 patients were included in the safety analysis (monotherapy studies: n = 1380; combination therapy studies: n = 2501). IRs for selected AEs of interest were generally numerically lower in patients who received tofacitinib 5 and 10 mg BID as monotherapy than as combination therapy (SAEs: IR [range] 6.21-6.72 versus IR 10.17-13.46; discontinuations due to AEs: IR 5.53-6.18 versus IR 10.80-11.01; serious infections: IR 1.57-1.66 versus IR 3.39-3.56; HZ: IR 1.95-2.93 versus IR 4.37-4.99, respectively), irrespective of tofacitinib dose or glucocorticoid use. There were too few patients and events within the placebo group to fully evaluate effect between combination therapy and monotherapy. CONCLUSIONS: Safety profiles were generally similar between patients receiving monotherapy and combination therapy; however, selected safety events of interest, including HZ and serious infections, showed lower IRs with non-overlapping 95% confidence intervals for tofacitinib all monotherapy versus combination therapy. Tofacitinib monotherapy may, therefore, have fewer safety events compared with combination therapy, and have a favorable risk-benefit profile in patients with active RA who are intolerant to csDMARDs.
引用
- Kivitz AJ, Cohen S, Keystone E, et al. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum. 2018. PMID: 30177460. doi:10.1016/j.semarthrit.2018.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。